Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

NCT ID: NCT01786915

Last Updated: 2014-04-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2013-03-31

Brief Summary

The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Bendavia 10mg

Bendavia capsule, 10mg, once daily for 7 days

Group Type: EXPERIMENTAL

Bendavia 10mg

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Placebo

Placebo (matching), once daily for 7 days

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Bendavia 50mg

Bendavia capsule, 50mg, once daily for 7 days

Group Type: EXPERIMENTAL

Bendavia 50mg

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Interventions

Bendavia 10mg

Intervention Type: DRUG

Bendavia 50mg

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

MTP-131; MTP-131

Eligibility Criteria

Inclusion Criteria

• Healthy adult males or females aged between 18 and 65 years of age with signed informed consent.
• Women who are not post-menopausal (without menstrual bleed for >24 months) or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment with understanding (through informed consent process) to not become pregnant over the duration of the study and must agree to employ an effective form of birth control for the duration of the study.

• Acceptable forms of birth control are: double-barrier contraceptives (condom, diaphragm with spermicide) or interuterine device (IUD) 1 week prior to and at least 30 days post treatment even if hormonal contraceptives are used.

Exclusion Criteria

• Serum sodium level below the lower limit of the site's clinical laboratory normal range at the study qualification visit,
• Clinically significant laboratory abnormalities as determined by the Principal Investigator at laboratory screening
• Creatinine clearance calculated by the Cockcroft and Gault method calculated to be <90 mL/min for males and <80 mL/min for females
• Clinically significant abnormalities on physical examination,
• Body weight less than 60 kg or greater than 80 kg or a body mass index of less than 18 kg/m2 or greater than 32 kg/m2,
• Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems,
• History of seizures or history of epilepsy,
• History of serious (Principal Investigator judgment) mental illness,
• Participant in any research involving investigational product within 30 days before planned date of drug administration,
• Positive serology for HIV 1, HIV 2, HBsAg, or hepatitis C virus (HCV),
• Fever greater than 37.5°C at the time of planned dosing,
• Suspicion, or recent history, of alcohol or substance abuse,
• Donated blood or blood products within the past 30 days,
• Women who are pregnant or breastfeeding,
• Employee or family member of an employee of the investigational site,
• Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products or who have used any tobacco product in the 30 days prior to screening,
• Subjects who are either unwilling to agree to refrain from use or found to be using:

• Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement periods
• Prescription medications from 14 days prior to and 7 days post treatment (excluding hormonal contraceptives)
• Hormonal contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to and 30 days post treatment
• Subjects having previous exposure to Bendavia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Stealth BioTherapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Straube, MD

Role: STUDY_DIRECTOR

Stealth BioTherapeutics Inc.

Kenneth C Lasseter, MD

Role: PRINCIPAL_INVESTIGATOR

Climincal Pharmacology of Miami Inc

Locations

Clinical Pharmacology of Miami Inc

Miami, Florida, United States

Countries

United States

Other Identifiers

SPIO-102

Identifier Type: -

Identifier Source: org_study_id